Large UK study finds no benefit to HIV antiviral in COVID-19

For the third time this month, researchers running a large clinical trial in the U.K. have released results likely to shape how physicians the world over treat COVID-19.
On Tuesday, investigators for the RECOVERY study announced that treatment with Kaletra, an antiviral therapy for HIV, was no better than usual care alone in preventing death among patients hospitalized with coronavirus disease. As a result, the trial committee decided to stop giving the drug in the study.